Published in Oncoimmunology on May 05, 2015
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology (2016) 0.84
Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy. Expert Opin Biol Ther (2016) 0.77
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58
Innate immune recognition of cancer. Annu Rev Immunol (2015) 1.52
Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res (2014) 1.19
NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. Sci Transl Med (2013) 1.12
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med (2015) 1.09
Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology (2013) 0.92
Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome. Oncoimmunology (2013) 0.91